Leukemia & lymphoma/Leukemia and lymphoma · 1995 · 13 citations · 36 references
MedicineHematologyOncologyCytogeneticsHematologic OncologyHematopathologyBone Marrow PathologyCancer CytogeneticsClinical CytogeneticsHematologic MalignanciesHematopoietic NeoplasmsMolecular CytogeneticsAcute LeukemiasAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentAcute Promyelocytic LeukemiaLeukemia ClassificationLeukemia CytogeneticsLeukemia PathologyPml-rara Fusion Gene
From 1990 to 1994, 3 patients with de novo acute myeloid leukemia (AML) in whom light microscopy and cytochemistry suggested a FAB subtype M3 variant were observed at our Institute. Immunophenotype showed HLA-DR-, CD13+, CD33+, CD2+, CD9+; promyelocytic features were also detected by electron microscopy. However, leukemic cells lacked both translocation t(15;17) and RAR alpha/PML genes rearrangement. These cases were considered to be 'M2 atypical' subtypes and they contribute to point out how cytogenetics and molecular biology are mandatory for a correct diagnosis of acute promyelocytic leukemia (APL) particularly because therapy with all trans retinoic acid (ATRA) is now the best treatment for APL. Nevertheless these 3 cases indicate that the atypical M2 subtype may be confused with the M3v if only cytochemistry, immunophenotype and electron microscopy are used in the defining the FAB subtypes.
36
Molecular cloning: A laboratory manual
Prescott L. Deininger · Analytical Biochemistry · 1990 · 86.2K citations
John M. Bennett, Daniel Catovsky, Marie‐Theregse Daniel et al. · British Journal of Haematology · 1976 · 5.6K citations
Medicine, Hematology, Pathology +17